Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL-007 in Chronic Hepatitis B
NCT03244085Phase 1Unknown
- Sponsor
- Qilu Pharmaceutical
- Start
- Aug 2017
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of QL-007 in Chronic Hepatitis B (CHB) (3 arms), sponsored by Qilu Pharmaceutical. Primary endpoint: Incidence of Adverse Events of QL-007 at Day 36. Status: unknown.
02
Drugs
QL-007
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT03244085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03244085.